
Labcorp Achieves 8.6% Revenue Growth and 16.3% Margin Expansion in Q3 2025
Labcorp Holdings Inc.Description
What this story covers
Labcorp's Q3 2025 10-Q shows 8.6% revenue growth to $3.56B, driven by Diagnostics (78% of revenues) and Biopharma segments. Operating income up 56.1%, with strong cash flows of $1.03B. Strategic acquisitions enhance genetics and market reach; hedges mitigate FX and rate risks amid stable liquidity.
Story snapshot
CompanyLabcorp Holdings Inc.
TickerLH
VariantStandard detailed
Duration13:10
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000920148-25-000096
Full Story Script
Content not available for this story.